Taken together, we propose that NFE2L3 promotes CRC through changes in the tumor microenvironment, by suppressing the activity of Tregs and through the activation of mast cells, mediated, at least in part, via the increase of IL33 expression and decrease of RAB pathway signaling. This evidence concerns the gene AGFG1 and colorectal carcinoma.